Capsugel CEO Driesen Plots Post-Pfizer Course
This article was originally published in The Tan Sheet
Executive Summary
Guido Driesen, president and CEO of Capsugel, says the oral dosage technology firm is having a record year after being divested by Pfizer. In an interview, he discusses the firm’s applications for OTC drugs and nutritionals, as well as Capsugel’s international expansion.
You may also be interested in...
New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.
New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.
Capsugel Flexes Breadth Of Capabilities In Development Collaborations
Amit Patel, president of Capsugel’s Dosage Form Solutions business unit, says the firm is able to work more closely with customers in the product development process since it is no longer a subsidiary of Pfizer. Capsugel announced the launch of its Lipidex integrated technology platform June 5.